Ancora Biotech lead clinical asset, TeneoTwo, to be acquired by AstraZeneca for up to $1.27B Notable Jul 5 Written By Frances Benson https://www.astrazeneca.com/media-centre/press-releases/2022/astrazeneca-to-acquire-teneotwo-and-t-cell-engager.html 2022 Frances Benson
Ancora Biotech lead clinical asset, TeneoTwo, to be acquired by AstraZeneca for up to $1.27B Notable Jul 5 Written By Frances Benson https://www.astrazeneca.com/media-centre/press-releases/2022/astrazeneca-to-acquire-teneotwo-and-t-cell-engager.html 2022 Frances Benson
